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Abstract 
Frailty has emerged as a reliable measure of the aging process. Because the early detection of frailty is crucial to 
prevent or even revert it, the use of biomarkers would allow an earlier and more objective identification of frail 
individuals. To improve the understanding of the biological features associated with frailty as well as to explore 
different biomarkers for its early identification, several genetic outcomes—mutagenicity, different types of genetic 
damage, and cellular repair capacity—were analyzed in a population of older adults classified into frail, prefrail, and 
nonfrail. Besides, influence of clinical parameters—nutritional status and cognitive status—was evaluated. No 
association of mutation rate or primary DNA damage with frailty was observed. However, DNA repair capacity 
showed a nonsignificant tendency to decrease with frailty, and persistent levels of phosphorylated H2AX, as 
indicative of DNA breakage, increased progressively with frailty severity. These results support the possible use of 
H2AX phosphorylation to provide information regarding frailty severity. Further investigation is necessary to 
determine the consistency of the current findings in different populations and larger sample sizes, to eventually 
standardize biomarkers to be used in clinics, and to fully understand the influence of cognitive impairment. 
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The concept of “frailty” has emerged in the last years as a more accurate and reliable measure of the 
aging process than the traditional chronological age. Frailty is a multidimensional geriatric syndrome of 
decreased reserves and resistance to stressors, resulting from cumulative declines across multiple 
physiological systems and causing vulnerability to adverse health outcomes, including dependency and 
death (1). Prevalence of frailty increases with age (2), and it has been reported to vary between 4.0% and 
59.1% across different studies, due to factors such as criteria employed for frailty identification, gender, 
race, socioeconomic conditions, or education (1,3). Despite being phenotypically well characterized, the 
biological basis of frailty still remains fairly unknown. This is due to the fact that this syndrome is not 
characterized by impairment of a single system, but by several events and anomalies in multiple 
physiological systems in an intricate process that leads to frailty (4). 
 
To date, identification of frail individuals is mainly performed in health care settings by using clinical 
features, although other approaches using standard laboratory tests have been reported (5,6). The most 
commonly employed diagnostic criteria, due to their simplicity of implementation, are those proposed by 
Fried and colleagues in 2001 (1), based on five phenotypic characteristics (muscle weakness, low gait 
speed, unintentional weight loss, exhaustion, and low physical activity). Another frequent approach is to 
calculate a frailty index, based on the accumulation of health deficits (7). Detection of frailty as soon as 
possible is crucial, because it is potentially preventable and can be even reverted in its early stages (8). 
Development of biomarkers for this syndrome would allow an earlier and more objective identification of 
frail individuals, but a deeper knowledge on the biological basis of frailty is required for this aim. In this 
regard, frailty is commonly accepted to have a strong biological component resulting from cumulative 
cellular damage over the life course (9), although other aspects of aging involving intercellular 
communication, breakdown of homeostasis at the organism level, and so on probably participate in frailty 
development. Increased levels of damage can lead to different cellular alterations, including genomic 
instability, mutations, altered gene expression, loss of cell division potential, cell death, or impaired 
intercellular communication, among others (10). These alterations at the cellular and molecular levels 
could be a good basis to establish frailty biomarkers. 
 
T-cell receptor (TCR) is a complex of integral membrane proteins that participate in the activation of 
T cells in response to an antigen. Induced or spontaneous mutations in TCR genes could result in the 
phenotypic expression of TCR-defective T cells and thus contribute to impairment of T-cell response. It 
has been suggested that TCR variant frequency might be a particularly relevant end point in population 
monitoring for genetic damage (11). Accordingly, this end point has been previously employed as a 
mutagenicity biomarker in biomonitoring studies of occupationally or medically exposed individuals 
(12,13), as well as a predictor of cancer risk (14). 
 
The alkaline single-cell gel electrophoresis (comet) assay is a simple and sensitive method to measure 
primary DNA damage in individual cells. Strand breaks cause relaxation of the supercoiling in the DNA, 
and free DNA loops are pulled toward the anode during electrophoresis, giving the appearance of a comet 
tail (15). 
 
The phosphorylation of the C-terminal of the variant core histone protein H2AX (γH2AX) at the 
highly conserved amino acid Ser139 is a quickly occurring event in the early DNA damage response to 
double-strand breaks (16). The half-life of γH2AX after DNA damage induction has been estimated to be 
2–7 hours; after this time, H2AX is again dephosphorylated (17). Still, it has been reported that γH2AX 
persistent in time represent DNA lesions with unrepairable double-strand breaks (18). 
 
DNA repair is one of the most important mechanisms to maintain genome integrity. Consequently, 
deficiencies in this process are often considered one of the key processes in the development of diseases 
such as cancer and other age-related pathologies (19). Indeed, it was previously suggested that one of the 
possible causes or events involved in frailty syndrome is the alteration of the cellular repair mechanisms 
that would result in the accumulation of genetic damage (9,10). 
  
Hence, to improve the understanding of the biological features associated with frailty status, and 
consequently set the basis to identify potential biomarkers of frailty, in the present study, several genetic 
parameters were analyzed in a population of older adults (aged 65 and older) classified into frail, prefrail, 
and nonfrail according to Fried’s criteria (1). Genetic outcomes analyzed included mutation rate (by 
means of the TCR mutation assay), different types of genetic damage (by employing the comet assay and 
the γH2AX assay), and cellular repair capacity (by the DNA repair competence assay). Besides, the 
influence of clinical parameters, namely nutritional status and cognitive status, was also evaluated. 
Method 
Participant Recruitment 
After obtaining approval from the University of A Coruña Ethics Committee (CE 18/2014), and 
following the principles embodied in the Declaration of Helsinki, peripheral blood samples were obtained 
by venipuncture from 250 volunteer donors, aged at least 65 years old, recruited from associations of 
elder people and nursing homes located in Galicia (NW of Spain). An informed consent form was signed 
by all participants in the study or by their relatives in case of inability. A questionnaire with information 
about demographics, lifestyle, and medical information was completed for each donor. The clinical 
evaluation of the participants was performed by qualified staff with extensive experience in the 
gerontology field, equally trained prior to the start of the study to unify criteria. Exclusion criteria 
included taking medications known to affect the immune system and having had cancer or any chronic 
infection (eg, human immunodeficiency virus, hepatitis B virus, hepatitis C virus). Characteristics of the 
study population are presented in Table 1. 
  
Table 1. Description of the Study Population 
 
Total  Nonfrail  Prefrail  Frail  
p 
Value  
      
Total individuals, N (%)  250 (100)  37 (14.8)  125 (50.0)  88 (35.2)    
Gender, N (%)            
 Male  81 (32.4)  25 (67.6)  34 (27.2)  22 (25.0)  <.001b  
 Female  169 (67.6)  12 (32.4)  91 (72.8)  66 (75.0)    
Age (y)a  79.4 ± 8.8 (65–102)  73.5 ± 5.6 (65–85)  76.7 ± 7.6 (65–100)  85.8 ± 7.9 (65–102)  <.001c  
 65–69  42 (16.9)  11 (29.7)  29 (23.2)  2 (2.3)  <.001b  
 70–74  39 (15.7)  10 (27.0)  25 (20.0)  4 (4.6)    
 75–79  47 (18.9)  10 (27.0)  24 (19.2)  13 (14.9)    
 80–84  44 (17.7)  5 (13.5)  25 (20.0)  14 (16.1)    
 ≥85  77 (30.9)  1 (2.7)  22 (17.6)  54 (62.1)    
Smoking habits, N (%)            
 Nonsmokers  195 (79.6)  21 (56.8)  98 (79.0)  76 (90.5)  <.001b  
 Ever smokers  50 (20.4)  16 (43.2)  26 (21.0)  8 (9.5)    
  Number of cigarettes/da  18.1 ± 14.0 (2–60)  15.8 ± 9.1 (3–40)  15.0 ± 13.9 (2–60)  31.4 ± 15.7 (20–60)  .018c  
  Years smokinga  26.5 ± 16.8 (4–66)  19.8 ± 9.4 (10–34)  29.8 ± 19.3 (4–66)  29.3 ± 18.2 (6–52)  0.244c  
Nutrition status, N (%)            
 Normal nutrition status  153 (62.4)  34 (91.9)  101 (80.8)  18 (21.6)  <.001b  
 At risk of malnutrition  78 (31.8)  3 (8.1)  22 (17.6)  53 (63.9)    
 Malnourished  14 (5.8)  —  2 (1.6)  12 (14.5)    
 MNA-SF scorea  11.8 ± 2.5 (4–14)  13.3 ± 1.3 (8–14)  12.7 ± 1.8 (4–14)  9.7 ± 2.4 (4–14)  <.001c  
BMI (kg/m2)a  28.5 ± 5.6 (16.5–
53.2)  
28.1 ± 3.2 (21.1–
35.1)  
29.1 ± 5.1 (18.9–
47.4)  
27.7 ± 6.9 (16.5–
53.2)  
0.188c  
Comorbidity, N (%)            
 No comorbidity  171 (68.6)  31 (83.8)  88 (70.4)  52 (59.8)  .047b  
 Low comorbidity  46 (18.5)  2 (5.4)  25 (20.0)  19 (21.8)    
 High comorbidity  32 (12.9)  4 (10.8)  12 (9.6)  16 (18.4)    
Cognitive status, N (%)            
 No cognitive impairment  169 (69.5)  37 (100)  114 (91.2)  18 (22.2)  <.001c  
 Cognitive impairment  74 (29.5)  —  11 (8.8)  63 (77.8)    
Living conditions, N (%)            
 Family home  149 (59.6)  37 (100)  107 (85.6)  5 (5.7)  <.001b  
 Family home + daycare 
center  
27 (10.8)  —  4 (3.2)  23 (26.1)    
 Nursing home  74 (29.6)  —  14 (11.2)  60 (68.2)    
Education years, N (%)            
 ≤8  111 (44.9)  19 (51.4)  69 (55.2)  23 (27.1)  <.001b  
 9–17  94 (38.1)  11 (29.7)  31 (24.8)  52 (61.2)    
 >17  42 (17.0)  7 (18.9)  25 (20.0)  10 (11.8)    
      
 
Note: BMI = body mass index; MNA-SF = Mini-Nutritional Assessment–Short Form. 
Bold values mean statistically significant, i.e., P < .05. 
aMean ± SD (range). bChi-square test (bilateral). cAnalysis of variance test (bilateral). 
 
 
  
Frailty Criteria 
Frailty status of the study participants was determined according to the five Fried’s phenotypic criteria 
(1): (a) shrinking or unintentional weight loss; (b) muscular weakness (grip strength); (c) self-reported 
exhaustion; (d) slow walk; and (e) low physical activity level. Individuals were classified as nonfrail, 
prefrail, or frail depending on the number of items they presented (none, 1–2, or ≥3, respectively). 
Clinical Evaluation 
The Spanish version (20) of the Mini-Nutritional Assessment–Short Form (21) was employed to 
assess the nutritional status of the participants. The score obtained in the questionnaire was used to 
classify participants with normal nutritional status (12–14 points), at risk of malnutrition (8–11 points), 
and malnourished (0–7 points). 
 
Cognitive status was evaluated using the Mini-Mental State Examination scale in its Spanish version 
(22). Scores of this questionnaire, ranging from 0 to 30, were adjusted for age and education level. 
Participants who scored less than or equal to 24 were considered as cognitively impaired (22). 
 
Charlson’s comorbidity index (23) was employed to determine general comorbidity and number of 
comorbid diseases. For each patient, an age-adjusted score was computed, coding comorbid diseases as 0 
= absent and 1–6 = present. This index was also used to examine whether the 10-year mortality rates from 
comorbid disease were significantly different among frailty groups. A composite comorbidity-age score 
was computed for each participant, and the 10-year mortality was evaluated using a theoretical low-risk 
population, whose 10-year survival was 98.3% (24). 
Blood Sample Collection and Lymphocyte Isolation 
Whole blood was collected into BD Vacutainer CPT Cell Preparation Tubes with sodium heparin 
(Becton Dickinson), for the isolation of peripheral blood mononuclear leukocytes (lymphocytes + 
monocytes) following manufacturer’s instructions. Fresh leukocytes were employed in the TCR mutation 
assay. For the comet, γH2AX, and DNA repair competence assays, isolated leukocytes were frozen at 
−80°C in a solution composed of 50% fetal calf serum, 40% RPMI 1640, and 10% dimethyl sulfoxide, at 
10
7
 cells/mL, and stored until analysis. All samples were coded at the moment of collection, to ensure a 
blind study. 
TCR Mutation Assay 
TCR mutation assay was conducted in duplicate following the protocol proposed by Akiyama and 
colleagues (25). In brief, leukocytes were stained with 7-amino-actinomycin D as a viability marker and 
with fluorescein isothiocyanate-labeled antiCD3 and phycoerythrin-labeled antiCD4 antibodies (Becton 
Dickinson). Cell suspensions were analyzed using a FACSCalibur flow cytometer (Becton Dickinson) 
with Cell Quest Pro software (Becton Dickinson). The lymphocyte population was gated according to size 
and complexity. A minimum of 2.5 × 10
5
 lymphocyte-gated events were acquired, and TCR mutation 
frequencies (TCR-Mf) were calculated as the number of events in the mutant cell window (CD3
−
CD4
+
 
cells) divided by the total number of events corresponding to CD4
+
 cells. 
  
Alkaline Comet Assay 
To conduct the alkaline comet assay, following the protocol previously described in Laffon and 
colleagues (26), leukocytes were rapidly thawed at 37°C and subsequently centrifuged. The remaining 
pellet was suspended in phosphate-buffered saline solution. Cell viability was assessed by trypan blue 
exclusion technique being, in all cases, higher than 85%. An internal standard (leukocytes isolated from 
whole blood extracted once from a single donor and stored aliquoted at −80°C) was introduced in every 
electrophoresis run as described by Cebuslka-Wasilewska (27). Comet IV software (Perceptive 
Instruments) was used for image capture and analysis. For all donors and standards, 50 cells were scored 
from each replicate slide (ie, 100 cells in total) by a single scorer. The percentage of DNA in the comet 
tail (%TDNA) was evaluated as DNA damage parameter. 
γH2AX Assay 
γH2AX analysis was performed in duplicate following the protocol previously described by Sánchez-
Flores and colleagues (28). Briefly, after being thawed, cell suspensions were centrifuged, and 
supernatants were removed. Remaining pellets were suspended in culture medium containing 1% 
phytohemagglutinin and incubated for 24 hours at 37°C. After fixation, cell suspensions were incubated 
with anti-human γH2AX-Alexa Fluor 488-conjugated antibody (Becton Dickinson) and stained with 
propidium iodide. Flow cytometry analysis was performed in a FACSCalibur flow cytometer (Becton 
Dickinson) with Cell Quest Pro software (Becton Dickinson). A minimum of 10,000 events in the 
lymphocyte region (gated according to size and complexity) were acquired, obtaining data from FL1 
(γH2AX-Alexa Fluor 488) and FL2 (propidium iodide) detectors. The percentage of gated events positive 
for both γH2AX and PI was calculated with respect to the total lymphocytes gated and indicated as 
%γH2AX. 
DNA Repair Competence Assay 
DNA repair competence assay was performed as previously described by Laffon and colleagues (29). 
In brief, after being rapidly thawed, leukocytes were centrifuged, and the remaining pellet was incubated 
for 24 hours at 37°C in culture medium containing 1% phytohemagglutinin. Cells were then treated with 
the challenging agent bleomycin for 30 minutes at 37°C to induce DNA damage. Two duplicate slides 
were prepared for each donor: The first ones from cells that continued the comet assay protocol as 
previously described directly after bleomycin treatment (labeled as before repair) and the second ones 
from cells that, after bleomycin treatment, were incubated in fresh culture medium for 15 minutes at 37°C 
to allow DNA repair (labeled as after repair), before being processed following the comet assay protocol. 
An internal standard was introduced as well in each experiment as described by Cebulska-Wasilewska 
(27). Final data are shown as percentage of repair capacity (%RC), calculated as follows: (%TDNABR − 
%TDNAAR) × 100/%TDNABR, where “BR” is before repair and “AR” is after repair. 
 
Leukocyte samples from several individuals (mostly frail and a few prefrail) were lost due to 
unexpected problems in storage. Hence, the number of data available in comet assay and DNA repair 
capacity evaluation is lower than in the rest of assays. 
Statistical Analysis 
Characteristics of the study population, namely sociodemographic factors (gender, age, living 
conditions, and years of education), lifestyle factors (smoking habit), and clinical characteristics (body 
mass index [BMI], nutrition status, comorbidity, and cognitive status), were compared in the three groups 
of older adults according to their frailty status. Analysis of variance and chi-square test were applied for 
continuous variables and categorical variables, respectively. 
  
The effect of frailty status on the genetic parameters was preliminarily tested through univariate 
analyses. Analysis of variance and Tukey’s post hoc test were applied to normally distributed parameters, 
according to Kolmogorov–Smirnov goodness-of-fit test (%γH2AX and log-transformed TCR-Mf). 
Kruskal–Wallis test and Bonferroni’s correction were applied to %TDNA and %RC because no better 
approximation to the normal distribution was achieved with transformation. 
 
Negative binomial regression models were used to estimate the effect of frailty status and other 
clinical parameters on TCR-Mf because this parameter is a count. The same effects on %γH2AX, 
%TDNA, and %RC were assessed by applying linear regression models on the log-transformed data. All 
models included gender, age, and smoking habit (never/ever smokers). Similar models were run adjusting 
also by BMI, but results obtained were very similar in all cases. The results are presented as mean ratios 
and 95% confidence intervals. 
 
Associations between genotoxicity parameters were estimated by Spearman’s rank correlation. 
Receiver-operating characteristic curves were computed to assess the biomarkers discriminating ability. 
The critical limit for significance was set at p less than .05. The statistical software used for the analyses 
were the IBM SPSS software package V. 20 (SPSS, Inc.) and the STATA/SE software package V. 12.0 
(StataCorp LP). 
Results 
The total population analyzed consisted of 250 individuals aged 65 and older (range 65–102; Table 1). 
Prefrail individuals were the most prevalent (half of the population), followed by frail participants 
(35.2%). Female gender was more frequent in the prefrail and frail groups, but the opposite occurred in 
the nonfrail group. As expected, mean age increased with frailty severity, and so did the prevalence of 
nonsmokers and individuals at risk of malnutrition and malnourished. Both the number of years smoking 
and BMI were homogeneously distributed among groups. Cognitive impairment was very frequent in frail 
individuals (77.8%), but it was absent in nonfrail participants. Most frail individuals lived in nursing 
homes, whereas all nonfrail individuals lived at family homes. Regarding years of education, distribution 
in the three education categories established was very similar for nonfrail and prefrail participants, with a 
higher prevalence of lower education level (51.4% and 55.2%, respectively), but middle education level 
was more prevalent among frail individuals (61.2%). 
 
Figure 1 shows the results of the different genetic parameters tested in the study population. 
According to the univariate analyses, no significant influence of frailty status on TCR-Mf, %TDNA, or 
%RC was obtained, although a clear tendency to decline in repair capacity with increasing frailty status 
was observed. Moreover, a significant (p < .01) and progressive increase of %γH2AX with frailty severity 
was also detected. 
 
  
 
 
 
Figure 1. Results of biomarkers analyzed in the study group, classified according to frailty status. Bars represent SEM. Different 
letters indicate statistically different groups (ANOVA and Bonferroni’s correction). ANOVA = analysis of variance; RC = repair 
capacity; TCR-Mf = T-cell receptor mutation frequency; TDNA = DNA in the comet tail; γH2AX = phosphorylated H2AX histone. 
Associations between genetic parameters tested were not obtained according to Spearman’s 
correlation. Nevertheless, when associations with micronucleus rate in peripheral lymphocytes previously 
determined in the current population (30) were tested, a significant correlation was obtained for the 
association with %γH2AX (r = .252, p < .001). Besides, %γH2AX and the number of positive frailty 
criteria also showed to be significantly correlated (r = .201, p < .01).  
 
Results obtained in the multivariate statistical analyses, adjusting by gender, age, and tobacco 
consumption (and alternatively adjusting by BMI), confirmed previous results from univariate analyses 
on the influence of frailty (Table 2), that is, increasing frailty severity was accompanied by a progressive 
decrease in repair capacity and increase in H2AX phosphorylation; significance was observed for this last 
parameter in frail individuals with regard to nonfrail (p < .05). TCR-Mf and comet assay results did not 
show any significant effect. No significant influences were obtained for gender, age, or smoking on any 
parameter tested, and including BMI in the models scarcely changed the results. 
  
Table 2. Effect of Frailty Status on the Biomarkers Analyzed 
 
TCR-Mf   %TDNA   %γH2AX   %RC  
Mean Ratio  95% CI   Mean Ratio  95% CI   Mean Ratio  95% CI   Mean Ratio  95% CI  
            
Frailty status                     
 Nonfrail  1.00     1.00     1.00     1.00    
 Prefrail  0.90  0.70–1.15   0.90  0.64–1.27   1.13  0.95–1.34   0.58  0.30–1.15  
 Frail  0.94  0.70–1.27   0.66  0.41–1.08   1.25*  1.03–1.53   0.46  0.18–1.23  
Gender                     
 Male  1.00     1.00     1.00     1.00    
 Female  0.99  0.81–1.22   1.27  0.93–1.72   1.00  0.87–1.15   1.17  0.63–2.18  
Age  1.00  0.99–1.01   1.00  0.99–1.01   1.01  0.99–1.01   0.98  0.95–1.02  
Smoking habits                     
 Nonsmokers  1.00     1.00     1.00     1.00    
 Smokers  1.16  0.92–1.47   0.98  0.70–1.38   1.09  0.93–1.28   1.03  0.55–1.95  
            
 
Note: CI = confidence interval; RC = repair capacity; TCR-Mf = T-cell receptor mutation frequency; TDNA = DNA in the comet 
tail; γH2AX = phosphorylated H2AX histone. Models adjusted for age, sex, and smoking habits. 
*p < .05. 
Given the positive influence of frailty on γH2AX assay results, and in order to determine the single 
contribution of each frailty criterion to γH2AX levels, this parameter was compared in the groups of 
participants negative and positive for each individual criterion (Figure 2). No differences were observed 
between individuals negative and positive for unintentional weight loss or exhaustion. However, 
significantly higher values of %γH2AX were observed in individuals positive for the criteria low physical 
activity (p < .001), slow waking time (p < .01), and low grip strength (p < .01) when compared with those 
individuals negative for each corresponding criterion. Comparisons of the other three genetic outcomes 
with regard to each individual frailty criterion did not produce any significant result. Moreover, when 
receiver-operating characteristic curve for %γH2AX was computed considering nonfrail and frail states, 
the area under the curve obtained was 0.723, which can be considered useful for some purposes, although 
not with high accuracy (31). Considering nonfrail and prefrail states, the area under the curve was lower 
(0.655). 
  
 
 
 
Figure 2. Percentage of H2AX phosphorylation in the older adult population, according to each frailty criterion (1). The number of 
individuals included in each group is indicated inside each rod. Bars represent SEM. **p < .01, ***p < .001, significant difference 
with regard to negative (Student’s t test). γH2AX = phosphorylated H2AX histone. 
Multivariate analyses were also applied to estimate the influence of other clinical parameters on the 
biomarkers tested. Nutritional status and comorbidity did not show significant effects on any biomarker. 
Notably, both TCR-Mf and %γH2AX increased significantly with the 10-year mortality risk estimation (p 
< .001 and p = .026, respectively), and significant correlations were found between 10-year mortality risk 
estimation and these parameters (r = .140, p = .029 for TCR-Mf, and r = .231, p = .001 for %γH2AX). 
Moreover, participants presenting cognitive impairment showed a significant 16% increase (95% 
confidence intervals = 1.02–1.31, p = .026) in the level of H2AX phosphorylation than participants with 
normal cognitive status. 
Discussion 
Frailty is a condition of vulnerability involving an increased risk of poor health outcomes in older 
adults. The use of biomarkers to identify frail individuals not only would be a more precise and objective 
method for frailty identification, but also would make epidemiological studies more comparable, allowing 
to draw suitable conclusions from them. Besides, they might have the potential of anticipating the 
recognition of frail individuals, thus helping to prevent or attenuate the negative outcomes of frailty. 
However, and despite the last evidence supporting the relationship between a number of cellular 
alterations and frailty (10), up to now no biological feature has been validated to be employed as a 
biomarker to identify frailty status. 
 
With the aim of developing biomarkers of frailty, our group has investigated the potential association 
of frailty status with different genetic and immunological outcomes (30,32). In a very recent study (30), 
we evaluated the suitability of micronucleus frequency—a biomarker of genomic instability—to be 
employed as frailty biomarker. In such study, micronucleus rate in peripheral lymphocytes revealed its 
potential to be used for this purpose, because it showed a progressive increase with frailty severity, 
notably differentiating the group of frail participants. However, discrimination of prefrail individuals was 
not so clear, which would have been desirable from the clinical point of view. Besides, the association 
between micronucleus frequency and frailty resulted highly influenced by patients’ cognitive status, an 
aspect not considered in the current Fried’s frailty scale. On this basis, further investigations were 
necessary to fully understand the association between DNA cumulative damage and frailty status. 
Therefore, in the present study, we addressed the possible relationship between frailty status and different 
genomic outcomes, chosen on the basis of their demonstrated link to aging or age-related diseases 
(16,33), in a population of frail, prefrail, and nonfrail older adults. 
  
In the present study, the first addressing the possible relationship between frailty and mutagenicity, 
TCR-Mf was not found to be influenced by frailty status or age. Contradictory results have been 
previously obtained regarding age effect on TCR-Mf in occupationally exposed populations entirely less 
than 65 years old, with both the absence (34) and the presence (13) of such influence. Besides, 
significantly positive and linear association between TCR-Mf and age was observed by Akiyama and 
colleagues (25), in a wide age range group of individuals (0–96 years). It is likely that the age range 
covered by our study population (65–102 years) was not wide enough to detect variations in TCR-Mf 
with age, because our results indicate that over the age of 65 years, mutation rate remains stable and 
independent of frailty status. 
 
In the present study, the possible association between frailty and alteration of the cellular repair 
mechanisms has been evaluated by means of the DNA repair competence assay. However, and despite 
repair capacity showed a tendency to decrease with frailty severity, no significant differences were 
reached. To the best of our knowledge, only the study of Collerton and colleagues (35) has previously 
evaluated the possible association between repair capacity and frailty status in the older adults (aged 85 
and older), and negative results were also obtained. In both cases, repair capacity was assessed using 
DNA damaging agents with similar action mechanism, namely ionizing radiation in Collerton and 
colleagues’ study and the radiomimetic agent bleomycin in the present study. These agents induce a wide 
spectrum of mutagenic lesions, including DNA base damage, abasic sites, and alkali-labile sites, which 
eventually result in DNA single- and double-strand breaks. Considering the demonstrated link between 
repair capacity and aging or age-related diseases (36), further investigations in this line, maybe using 
other assays to assess different repair pathways, are required prior fully rejecting DNA repair influence on 
frailty status. 
 
Primary DNA damage was determined by means of alkaline comet assay, but no association with 
frailty status was found in the present study. Similarly, Collerton and colleagues (35) reported a lack of 
association between genetic damage (γ ray–induced DNA strand breakage, evaluated by fluorimetric 
detection of alkaline DNA unwinding) and frailty condition in an older adult population aged 85 years 
and older. No other studies evaluating genetic damage in frail individuals are available in the literature; 
however, there are a number of works addressing the association between this kind of genetic damage and 
age showing inconsistent results. For instance, Humphreys and colleagues (37) found a decrease in DNA 
damage in the oldest group (aged 75–82 years) with respect to the young controls (aged 20–35 years) and 
to the younger older people (aged 63–70 years). Hyland and colleagues (38) reported similar levels of 
DNA damage in older individuals (86–96 years old) that in middle-aged individuals (40–60 years). On 
the contrary, Mladinic and colleagues (39) (age group ranges: 35–47 and 65–76 years old), Piperakis and 
colleagues (40) (age group ranges: children: 5–10; adults: 40–50; old people: 70–80 years old), and 
Mutlu-Türkoglu and colleagues (41) (age group ranges: 21–40 and 61–85 years old) observed an increase 
of DNA damage with age. Several authors have previously pointed out that results obtained in the 
alkaline comet assay are highly variable and often difficult to interpret because several types of damage 
are detected—including single- and double-strand breaks, alkali-labile sites, and breaks generated during 
repair processes—and can be influenced by a number of variables (season, diet, sample collection time, 
etc.) (42). 
 
Opposite to comet assay, γH2AX assay determines not a wide spectrum of DNA lesions but a specific 
kind of damage, namely double-strand breaks. In the present study, a progressive increase in the γH2AX 
rate with frailty severity not influenced by age was observed, statistically significant in both prefrail and 
frail groups when compared with the nonfrail groups. Besides, participants with cognitive impairment 
showed an increase in %γH2AX with respect to those with normal cognitive status. Silva and colleagues 
(43) also reported an increase in γH2AX nuclear expression levels in individuals with Alzheimer’s 
disease with regard to healthy individuals, and we previously found that the presence of cognitive 
impairment and frailty was independently related to an increase in the frequency of micronuclei in 
lymphocytes (30). These results would suggest a connection between cognitive impairment and frailty 
status and give support to the quite recently coined term “cognitive frailty,” introduced in an attempt to 
encapsulate the cognitive decline that is often observed in nondemented older adults who are physically 
frail, with an underlying pathophysiology different from that driving the cognitive trajectory in 
neurodegenerative disorders (44). 
 
Although the present study is the first one in evaluating the relationship of H2AX phosphorylation 
with frailty status, the relationship between cellular senescence and persistent γH2AX, as indicative of 
unrepaired double-strand breaks, has been already suggested by several authors (16,18). Still, Schurman 
and colleagues (45) reported that γH2AX endogenous levels increase with age, peaking at ~57 years, 
which is in agreement with the absence of influence of age in the present study, where all participants 
were 65 and older. 
 
Both comet assay and H2AX assay detect double-strand breaks, but their results do not always 
coincide. Although γH2AX was found to be associated with frailty in the present study, several reasons 
could explain the lack of association for comet assay. On the one hand, whereas comet assay usually 
reveals recently induced and easily repairable DNA damage (46), γH2AX levels reflect fixed genetic 
damage or DNA damage that could not be properly repaired (47). On the other hand, it is not absolutely 
clear whether γH2AX foci in fact always reflect the presence of DNA breakage (48). For example, aging 
hematopoietic stem cells have been reported to harbor replication stress-induced nucleolar γH2AX foci, 
which persist due to ineffective H2AX dephosphorylation rather than ongoing genetic damage (49). 
Nevertheless, the significant association found in the current older adult population between γH2AX 
levels and micronucleus frequency in peripheral lymphocytes (30), both indicative of persistent DNA 
damage, points to unrepaired double-strand breaks as the outcome influenced by frailty status and by 
cognitive impairment, according to the results obtained in the multivariate analyses. Multivariate models 
were adjusted by gender, age, and smoking habit—parameters known to influence results of genetic 
outcomes—but adjustment for other different confounders should be considered in further studies. 
 
Besides, parallel results between γH2AX assay (this study) and micronucleus test (30) were also 
obtained when analyzing each five frailty phenotypic criteria independently. Thus, major contribution of 
physical activity, walking time, and grip strength to variation of %γH2AX and micronucleus frequency 
was observed, whereas unintentional weight loss and exhaustion did not contribute, or contributed only 
minimally, to both parameter modifications. These similar results in γH2AX and micronucleus assays 
provide further support to the relationship between fixed genetic damage and frailty and also suggest that 
combinations of some phenotypic criteria and biomarkers might improve frailty identification. 
Furthermore, because different frailty indices calculated on the basis of routine laboratory measurements 
have been reported to be useful for identifying older adults at increased risk of death (5,6), maybe the 
combination of biomarkers of genetic damage with standard laboratory biomarkers would enhance 
preclinical detection of at-risk individuals, also helping to understand the underlying biological processes 
of frailty. 
 
Strengths and limitations of the phenotype criteria selected for identifying frailty in this study must be 
mentioned. Fried’s criteria have a solid foundation of biological causative theory (1). Frailty phenotype 
has been applied to multiple epidemiological studies where it is predictive of adverse clinical outcomes 
and, together with Rockwood and Mitnitski’s frailty index, appear to be the most robust assessment tools 
for use by clinicians and researchers today (reviewed in ref. (9)), Nevertheless, it includes measurements 
not routinely used for patient assessment, it does not cover psychosocial components of frailty (9), and 
cognitive impairment may lead to diagnostic failure in all five criteria (50). Hence, further investigation is 
needed to figure out whether H2AX phosphorylation and micronucleus rates are also related to frailty as 
identified by other evaluation tools. 
  
Conclusions 
In the present study, we addressed the possible relationship between different genetic outcomes—
namely mutagenicity, genetic damage, and cellular repair capacity—and frailty status by evaluating a 
population of older adults classified as frail, prefrail, and nonfrail according to the commonly used 
phenotypic criteria. No association of TCR-Mf and primary DNA damage with frailty was observed. 
DNA repair capacity showed a nonsignificant tendency to decrease with frailty, and the persistent levels 
of γH2AX increased progressively and significantly with frailty severity. 
 
Taking together our present results and the previous ones of micronucleus frequency in peripheral 
lymphocytes (30), the hypothesis that there is indeed a link between genomic instability, understood as 
fixed genetic damage, and frailty status seems to be plausible and supported by our data. Because both 
biomarkers, γH2AX and micronucleus rates, resulted significantly and progressively increased with 
frailty, they could be preliminarily proposed as tools for frailty identification or prediction (Figure 3); 
still, this is only an initial proposal and further validation is required to confirm the existence of this 
association and its specificity with frailty status and not through other age-related conditions probably 
associated with frailty. Besides, as γH2AX level resulted altered in both prefrail and frail groups, whereas 
micronucleus frequency was significantly increased only in frail individuals, a combination of both 
parameters could provide useful information regarding frailty severity, which would help clinicians to 
distinguish between prefrail and frail status and assisting them to offer personalized care. Consequently, 
results reported in the present study may contribute to improve health care/therapeutic strategies in older 
patients. Nevertheless, further investigation is necessary to prove whether the current findings are 
consistent and reproducible in larger sample sizes and different populations that may differ in the 
presence of other factors not considered in the analysis, to eventually standardize these biomarkers before 
they can be used in clinics, and to fully understand the influence of cognitive impairment on the results 
obtained. 
 
 
 
Figure 3. Relationship between frailty and genetic outcomes analyzed in the study population. Biomarkers of mutagenicity, primary 
DNA damage, and cellular repair capacity do not show differences according to frailty status. MN frequency discriminates between 
nonfrail and frail individuals, meanwhile γH2AX levels are different in nonfrail, prefrail, and frail groups. A combination of both 
MN and γH2AX rates shows potential to be employed in frailty identification. MN = micronucleus; γH2AX = phosphorylated 
H2AX histone; TCR = T-cell receptor. 
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